Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    DARPA P3 Researchers Race to Create Treatment for the Novel Coronavirus

    By Global Biodefense StaffMarch 11, 2020
    Misook Choe, a Laboratory Manager with the Emerging Infectious Disease branch at the Walter Reed Army Institute of Research, conducts studies in order to find a solution for the Coronavirus, March 3, 2020. Courtesy: DoD
    Share
    Facebook LinkedIn Reddit Email

    Researchers working under DARPA’s Pandemic Preparedness Platform (P3) are racing to apply their experimental techniques to a true pandemic playing out in real time.

    The clock begins ticking as soon as a blood sample is taken from a person who has fully recovered from the disease of interest. Then the researchers screen that sample to find all the protective antibodies the person’s body has made to fight off the virus or bacteria. They use modeling and bioinformatics to choose the antibody that seems most effective at neutralizing the pathogen, and then determine the genetic sequence that codes for the creation of that particular antibody. That snippet of genetic code can then be manufactured quickly and at scale, and injected into people.

    This approach is much faster than manufacturing the antibodies themselves. Once the genetic snippets are delivered by an injection, “your body becomes the bioreactor” that creates the antibodies. The P3 program’s goal is to have protective levels of the antibodies circulating within 6 to 24 hours.

    Read more: DARPA Races To Create a “Firebreak” Treatment for the Coronavirus – IEEE Spectrum

    COVID-19 DARPA Editor Pick Public Health Emergency SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleCongressional Leaders on Ways and Means Ask IRS to Reconsider Tax Deadline Given Coronavirus Crisis
    Next Article ASM Expresses Concern About Coronavirus Test Reagent Shortages

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.